Twitter/X

Omanta (YC S26) is a personalized research lab founded by Alfredo Gonzalez, PhD…

Brief

Omanta (YC S26) is a personalized research lab founded by Alfredo Gonzalez, PhD, and Ranad Humeidi, PhD, that claims to integrate full medical records and personal genomics with modern evidence to map therapies and launch bespoke campaigns. The company highlights Alfredo’s role in the personalized campaign behind Sid Sijbrandij’s reported complete remission and offers approaches like vaccines, CAR‑T, repurposing, expanded access, and continuous molecular monitoring.

Why it matters

Omanta (YC S26) is a personalized research lab founded by Alfredo Gonzalez, PhD, and Ranad Humeidi, PhD; Alfredo is credited with leading the personalized therapeutic campaign behind GitLab founder Sid Sijbrandij's complete remission.

Key details

  • Omanta integrates a patient’s full medical record and personal genomics with current scientific evidence to map existing and emerging therapies and, when needed, launches bespoke campaigns to build treatments (personalized vaccines, CAR‑T, drug repurposing, expanded access, continuous molecular monitoring).
  • Founders met eight years ago during CRISPR cancer research at the Broad Institute; Alfredo has a PhD in bioinformatics from UCLA and research experience at Broad/UCLA/Harvard, while Ranad has a PhD in chemical biology from Harvard and ran rare‑cancer programs for individual patients.
Source evidence

these cancer researchers led the personalized therapeutic campaign for gitlab founder Sid Sijbrandij's complete remission.

the real deal!

love working with them.

if you have a loved one with cancer, please share this with them.

they can save their life!

Omanta Health (@Omantahealth)

Introducing Omanta (YC S26) the personalized research lab for each patient.

Omanta integrates a patient's full medical record, personal genomics, and the latest scientific evidence to understand the molecular drivers of their disease. It maps existing and emerging therapies against their biology. And when the right treatment doesn't exist yet, it launches a personalized campaign to build it.

Even the hardest cases rarely have a team dedicated to solving them. Physicians make high-stakes calls with limited time, while data and therapies emerge every week. Science moves fast, but reaching the patient can take years.

That's the gap Omanta was built to close.

Founders Alfredo Gonzalez, PhD and Ranad Humeidi, PhD spent years on some of the most difficult cancer cases. Alfredo led the personalized therapeutic campaign behind Sid Sijbrandij's complete remission. Together they've worked with leading institutions on personalized vaccines, CAR-T, drug repurposing, expanded access, and continuous molecular monitoring. They've seen what becomes possible when the full force of modern science is organized around one person.

They met eight years ago doing early CRISPR cancer research at the Broad Institute of MIT and Harvard. Alfredo Gonzalez (CEO) has a PhD in bioinformatics from UCLA and led research projects across the Broad Institute, UCLA, and Harvard. Ranad Humeidi (CSO) has a PhD in chemical biology from Harvard, and has built and run rare-cancer programs for individual patients when standard options ran out.

omanta.com
A research lab, for one.

Linked-in: bit.ly/omanta-linkedin
YC Launch: bit.ly/omanta-yc

Video

— https://nitter.net/Omantahealth/status/2084696480829628826#m